Valneva SE (0OB3.L)
EUR 3.21
(4.28%)
EUR 3.21
(4.28%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 153.71 Million EUR | -57.46% |
| 2022 | 361.3 Million EUR | 3.8% |
| 2021 | 348.08 Million EUR | 215.52% |
| 2020 | 110.32 Million EUR | -12.58% |
| 2019 | 126.19 Million EUR | 11.64% |
| 2018 | 113.03 Million EUR | 7.35% |
| 2017 | 105.29 Million EUR | 11.94% |
| 2016 | 94.06 Million EUR | 20.04% |
| 2015 | 78.35 Million EUR | 112.22% |
| 2014 | 36.92 Million EUR | 21.28% |
| 2013 | 30.44 Million EUR | 787.35% |
| 2012 | 3.43 Million EUR | -66.57% |
| 2011 | 10.26 Million EUR | 22.25% |
| 2010 | 8.39 Million EUR | 171.16% |
| 2009 | 3.09 Million EUR | -9.42% |
| 2008 | 3.41 Million EUR | 294.69% |
| 2007 | 866 Thousand EUR | -62.82% |
| 2006 | 2.32 Million EUR | -22.65% |
| 2005 | 3.01 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 32.75 Million EUR | -21.83% |
| 2024 Q2 | 38.06 Million EUR | 16.2% |
| 2023 Q3 | 38.07 Million EUR | -5.38% |
| 2023 Q1 | 33.5 Million EUR | -69.92% |
| 2023 Q4 | 41.89 Million EUR | 10.05% |
| 2023 Q2 | 40.23 Million EUR | 20.08% |
| 2023 FY | 153.71 Million EUR | -57.46% |
| 2022 Q2 | 71.37 Million EUR | 226.69% |
| 2022 FY | 361.3 Million EUR | 3.8% |
| 2022 Q4 | 111.4 Million EUR | -28.9% |
| 2022 Q3 | 156.67 Million EUR | 119.51% |
| 2022 Q1 | 21.84 Million EUR | -92.15% |
| 2021 Q2 | 24.28 Million EUR | 4.61% |
| 2021 Q1 | 23.21 Million EUR | -54.9% |
| 2021 FY | 348.08 Million EUR | 215.52% |
| 2021 Q3 | 22.34 Million EUR | -7.99% |
| 2021 Q4 | 278.23 Million EUR | 1145.13% |
| 2020 Q3 | 10.94 Million EUR | -13.76% |
| 2020 FY | 110.32 Million EUR | -12.58% |
| 2020 Q2 | 12.68 Million EUR | -63.98% |
| 2020 Q1 | 35.22 Million EUR | -21.39% |
| 2020 Q4 | 51.47 Million EUR | 370.46% |
| 2019 Q2 | 19.65 Million EUR | -43.61% |
| 2019 FY | 126.19 Million EUR | 11.64% |
| 2019 Q4 | 44.8 Million EUR | 66.65% |
| 2019 Q3 | 26.88 Million EUR | 36.79% |
| 2019 Q1 | 34.85 Million EUR | 0.43% |
| 2018 Q2 | 26.88 Million EUR | -16.2% |
| 2018 Q1 | 32.08 Million EUR | 10.82% |
| 2018 FY | 113.03 Million EUR | 7.35% |
| 2018 Q4 | 34.7 Million EUR | 79.25% |
| 2018 Q3 | 19.36 Million EUR | -27.98% |
| 2017 Q2 | 25.41 Million EUR | -10.65% |
| 2017 Q4 | 28.94 Million EUR | 28.76% |
| 2017 Q3 | 22.48 Million EUR | -11.54% |
| 2017 FY | 105.29 Million EUR | 11.94% |
| 2017 Q1 | 28.44 Million EUR | 9.27% |
| 2016 Q4 | 26.03 Million EUR | 41.51% |
| 2016 FY | 94.06 Million EUR | 20.04% |
| 2016 Q3 | 18.39 Million EUR | -28.95% |
| 2016 Q2 | 25.89 Million EUR | 9.02% |
| 2016 Q1 | 23.74 Million EUR | 13.36% |
| 2015 Q2 | 18.59 Million EUR | -0.11% |
| 2015 Q1 | 18.61 Million EUR | 61.92% |
| 2015 FY | 78.35 Million EUR | 112.22% |
| 2015 Q4 | 20.94 Million EUR | 3.68% |
| 2015 Q3 | 20.2 Million EUR | 8.68% |
| 2014 Q3 | 11.07 Million EUR | 37.16% |
| 2014 FY | 36.92 Million EUR | 21.28% |
| 2014 Q1 | 6.28 Million EUR | -29.26% |
| 2014 Q2 | 8.07 Million EUR | 28.55% |
| 2014 Q4 | 11.49 Million EUR | 3.81% |
| 2013 Q3 | 13.82 Million EUR | 97.37% |
| 2013 Q4 | 8.87 Million EUR | -35.79% |
| 2013 FY | 30.44 Million EUR | 787.35% |
| 2013 Q1 | 737 Thousand EUR | -17.65% |
| 2013 Q2 | 7 Million EUR | 850.47% |
| 2012 Q3 | 1.03 Million EUR | 0.0% |
| 2012 Q4 | 895 Thousand EUR | -13.28% |
| 2012 FY | 3.43 Million EUR | -66.57% |
| 2011 FY | 10.26 Million EUR | 22.25% |
| 2010 FY | 8.39 Million EUR | 171.16% |
| 2009 FY | 3.09 Million EUR | -9.42% |
| 2008 FY | 3.41 Million EUR | 294.69% |
| 2007 FY | 866 Thousand EUR | -62.82% |
| 2006 FY | 2.32 Million EUR | -22.65% |
| 2005 FY | 3.01 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Boiron SA | 493.24 Million EUR | 68.837% |
| Laboratorios Farmaceuticos Rovi, S.A. | 829.5 Million EUR | 81.47% |
| Vetoquinol SA | 529.27 Million EUR | 70.958% |
| AB Science S.A. | 970 Thousand EUR | -15746.598% |
| Nanobiotix S.A. | 30.05 Million EUR | -411.385% |
| PHAXIAM Therapeutics S.A. | 1.32 Million EUR | -11492.157% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 4346.188% |
| BioSenic S.A. | 543 Thousand EUR | -28207.919% |
| ABIVAX Société Anonyme | 4.62 Million EUR | -3226.38% |
| Formycon AG | 77.69 Million EUR | -97.838% |